Merck & Co to buy $1bn stake in Seattle Genetics

16-09-2020

Sarah Morgan

Merck & Co to buy $1bn stake in Seattle Genetics

Katherine Welles / Shutterstock.com

Merck & Co is set to make a $1 billion investment in biotech company Seattle Genetics, as the companies collaborate to develop and sell Seattle Genetics’ cancer therapy, ladiratuzumab vedotin.


Merck & Co, Seattle Genetics, oncology, biotech, cancer therapy, Keytruda, collaboration

LSIPR